natgillin/translations-raw huggingface dataset:
MARKETING AUTHORISATION NUMBER(S) EU/1/09/596/007 
12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/09/596/007
Uncommon: Neutropenia and anaemia (both occasionally severe), thrombocytopenia. 
Manje često: neutropenija i anemija (ponekad teške), trombocitopenija.
Lamivudine 8 mg/kg OnceDaily Dosing Geometric Mean (95% Cl) 
Lamivudin 8 mg/kg jedanput na dan - geometrijska srednja vrijednost (95% Cl)
Other possible side effects of combination therapy for HIV Combination therapy including Lamivudine Teva Pharma B.V. may cause other conditions to develop during HIV treatment. 
Druge moguće nuspojave kombinirane terapije za HIV Kombinirana terapija koja sadrži Lamivudin Teva Pharma B.V. može uzrokovati razvoj drugih bolesti i stanja tijekom liječenja HIV-a.
Children weighing at least 20 kg and less than 25 kg The usual dose of Lamivudine Teva Pharma B.V. is 225 mg a day. 
Djeca tjelesne težine najmanje 20 kg, ali manje od 25 kg Uobičajena doza lijeka Lamivudin Teva Pharma B.V. je 225 mg na dan.
Children receiving lamivudine oral solution concomitantly with other antiretroviral oral solutions in clinical trials developed viral resistance more frequently than children receiving tablets (see the description of the clinical experience in paediatric population (ARROW study) and section 5.2). 
U djece koja su u kliničkim ispitivanjima primala oralnu otopinu lamivudina istodobno s drugim antiretrovirusnim lijekovima u obliku oralne otopine virusna rezistencija razvila se češće nego u djece koja su primala tablete (vidjeti opis kliničkog iskustva u pedijatrijskoj populaciji (ispitivanje
Not everyone responds to treatment with Lamivudine Teva Pharma B.V. in the same way. 
Ne reagiraju svi jednako na liječenje lijekom Lamivudin Teva Pharma B.V.
Lamivudine Teva Pharma B.V. is used to treat HIV (human immunodeficiency virus) infection in adults and children. 
Lamivudin Teva Pharma B.V. primjenjuje se za liječenje infekcija HIV-om (virusom humane imunodeficijencije) u odraslih i djece.
An oral solution is also available for the treatment of children over 3 months of age, or for people who need a lower dose than usual, or who cannot take tablets. 
Za liječenje djece u dobi od više od 3 mjeseca ili ljudi koji trebaju manju dozu od uobičajene ili koji ne mogu uzimati tablete dostupna je oralna otopina.
• emtricitabine (used to treat HIV infection). 
• emtricitabin (koji se primjenjuju za liječenje infekcija HIV-om)
White opaque HDPE tablet containers with white opaque polyethylene child resistant screw cap with induction seal. 
Bijeli neprozirni spremnici od polietilena visoke gustoće s bijelim neprozirnim polietilenskim sigurnosnim zatvaračem za djecu s navojem i zatvoreni zalijepljenom zaštitnom folijom.
If you forget to take Lamivudine Teva Pharma B.V. 
Ako ste zaboravili uzeti Lamivudin Teva Pharma B.V.
However, unless the patient has renal impairment, no dosage adjustment of lamivudine is necessary (see section 4.2). 
Međutim prilagodba doze nije potrebna osim ako bolesnik nema i oštećenu funkciju bubrega (vidjeti dio 4.2.).
Absorption differences have been observed between adult and paediatric populations (see “Special populations”). 
Između odrasle i pedijatrijske populacije primijećene su razlike u apsorpciji
Tablet film coat Hypromellose 3cP Hypromellose 6cP Titanium dioxide Macrogol 400 
Film-ovojnica tablete: hipromeloza 3cP hipromeloza 6cP titanijev dioksid makrogol 400 polisorbat 80 željezov oksid, žuti željezov oksid, crni
Lamivudine Teva Pharma B.V. is a type of medicine known as an antiretroviral. 
Lamivudin Teva Pharma B.V. je antiretrovirusni lijek.
This may be administered as either 150 mg twice daily or 300 mg once daily (see section 4.4). 
Preporučena doza lamivudina je 300 mg na dan, primijenjeno ili kao 150 mg dvaput na dan ili 300 mg jedanput na dan (vidjeti dio 4.4).
Plasma HIV-1 RNA <80 c/mL Risk difference (once daily-twice daily) 
HIV-1 RNK u plazmi <80 kopija/ml Razlika u riziku (jedanput na dan-dvaput na dan)
Lamivudine Teva Pharma B.V. 300 mg film-coated tablets Grey, diamond shaped, biconvex film-coated tablet with approx. 18.0 mm length and 8.0 mm widthengraved with “L 300” on one side and plain on the other 
Lamivudin Teva Pharma B.V. 300 mg filmom obložene tablete Siva, bikonveksna, filmom obložena tableta u obliku dijamanta, oko 18,0 mm duga i 8,0 mm široka, s utisnutom oznakom “L 300” na jednoj strani i bez oznake na drugoj strani.
Paediatric population: a randomised comparison of a regimen including once daily vs twice daily dosing of abacavir and lamivudine was undertaken within a randomised, multicentre, controlled study of HIV-infected, paediatric patients. 
Pedijatrijska populacija: u sklopu randomiziranog, multicentričnog, kontroliranog ispitivanja s pedijatrijskim bolesnicima zaraženima HIV-om provedena je randomizirana usporedba režima primjene abakavira i lamivudina jedanput na dan u odnosu na režim primjene dvaput na dan.
Lamivudine Teva Pharma B.V. 300 mg film-coated tablets EU/1/09/596/008 20 tablets (blister) EU/1/09/596/009 30 tablets (blister) EU/1/09/596/010 60 tablets (blister) EU/1/09/596/011 90 tablets (blister) EU/1/09/596/012 100 tablets (blister) EU/1/09/596/013 500 tablets (blister) EU/1/09/596/014 30 tablets (bottle) EU/1/09/596/016 80 tablets(blister) 
Lamivudin Teva Pharma B.V. 300 mg filmom obložene tablete EU/1/09/596/008 20 tableta (blister) EU/1/09/596/009 30 tableta (blister) EU/1/09/596/010 60 tableta (blister) EU/1/09/596/011 90 tableta (blister) EU/1/09/596/012 100 tableta (blister) EU/1/09/596/013 500 tableta (blister) EU/1/09/596/014 30 tableta (boca) EU/1/09/596/016 80 tableta (blister)
• cladribine (used to treat hairy cell leukaemia). 
• kladribin (koji se primjenjuje za liječenje leukemije vlasastih stanica).
Hepatic impairment: Data obtained in patients with moderate to severe hepatic impairment shows that lamivudine pharmacokinetics are not significantly affected by hepatic dysfunction. 
Podaci u bolesnika s umjerenim do teškim oštećenjem jetre pokazuju da oštećenje jetre ne utječe značajno na farmakokinetiku lamivudina.
Lamivudine Teva Pharma B.V. is indicated as part of antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infected adults and children. 
Lamivudin Teva Pharma B.V. je indiciran u kombinaciji s drugim antiretrovirusnim lijekovima za liječenje odraslih osoba i djece zaraženih virusom humane imunodeficijencije (HIV).
Other medicines and Lamivudine Teva Pharma B.V. 
Drugi lijekovi i Lamivudin Teva Pharma B.V.
These medicines should not be used with Lamivudine Teva Pharma B.V.: 
Sljedeći se lijekovi ne smiju primjenjivati istovremeno s lijekom Lamivudin Teva Pharma B.V.:
No studies on the effects on the ability to drive and use machines have been performed. 
4.7 Utjecaj na sposobnost upravljanja vozilima i rada sa strojevima Nisu provedena ispitivanja o utjecaju lamivudina na sposobnost upravljanja vozilima i rada sa strojevima.
Lamivudine Teva Pharma B.V. is available in aluminium blisters containing 20, 30, 60, 80, 90, 100 and 500 tablets or HDPE containers containing 60 tablets. 
Lamivudin Teva Pharma B.V. dostupan je u aluminijskim blisterima s 20, 30, 60, 80, 90, 100 i 500
INFORMATION IN BRAILLE Lamivudine Teva Pharma B.V. 300 mg 
16. PODACI NA BRAILLEOVOM PISMU Lamivudin Teva Pharma B.V. 300 mg
However, for the treatment of HIV infection only a 300 mg daily dose of lamivudine (in combination with other antiretroviral agents) has been shown to be efficacious. 
Međutim, za liječenje HIV infekcije djelotvorna je jedino doza od 300 mg na dan
Lamivudine Teva Pharma B.V. is unlikely to affect your ability to drive or use machines. 
Mala je vjerojatnost utjecaja lijeka Lamivudin Teva Pharma B.V. na sposobnost upravljanja vozilima i strojevima.
What you need to know before you take Lamivudine Teva Pharma B.V. Do not take Lamivudine Teva Pharma B.V. 
Što morate znati prije nego počnete uzimati Lamivudin Teva Pharma B.V.
• tingling or numbness of the arms, legs, hands or feet. 
• laktacidoza (nakupljanje mliječne kiseline u krvi) • osjećaj trnjenja ili ukočenosti ruku, nogu, šaka ili stopala.
These may affect up to 1 in 1000 people: 
Rijetke nuspojave Mogu se javiti kod najviše 1 od 1000 ljudi:
The nucleoside analogues (e.g. didanosine) like zidovudine, are not eliminated by this mechanism and are unlikely to interact with lamivudine. 
didanozin ) ne izlučuju se putem tog mehanizma i nisu vjerojatne njihove interakcije s lamivudinom.
Lamivudine Teva Pharma B.V. 150 mg film-coated tablets EU/1/09/596/001 20 tablets (blister) EU/1/09/596/002 30 tablets (blister) EU/1/09/596/003 60 tablets (blister) EU/1/09/596/004 90 tablets (blister) EU/1/09/596/005 100 tablets (blister) EU/1/09/596/006 500 tablets (blister) EU/1/09/596/007 60 tablets (bottle) EU/1/09/596/015 80 tablets (blister) 
150 mg filmom obložene tablete EU/1/09/596/001 20 tableta (blister) EU/1/09/596/002 30 tableta (blister) EU/1/09/596/003 60 tableta (blister) EU/1/09/596/004 90 tableta (blister) EU/1/09/596/005 100 tableta (blister) EU/1/09/596/006 500 tableta (blister) EU/1/09/596/007 60 tableta (boca) EU/1/09/596/015 80 tableta (blister)
General disorders and administration site conditions Common: Fatigue, malaise, fever. 
Opći poremećaji i reakcije na mjestu primjene Često: umor, slabost, vrućica
Cases of osteonecrosis have been reported, particularly in patients with generally acknowledged risk factors, advanced HIV disease or long-term combined antiretroviral exposure (CART). 
naročito u bolesnika s uznapredovalom HIV bolešću i/ili dugotrajnom izloženošću kombiniranom antiretrovirusnom liječenju.
150 mg once daily 
150 mg 100 mg jedanput na dan
The active ingredient in Lamivudine Teva Pharma B.V. is lamivudine. 
Djelatna tvar u lijeku Lamivudin Teva Pharma B.V. je lamivudin.
In vitro data tend to suggest that the continuation of lamivudine in anti-retroviral regimen despite the development of M184V might provide residual anti-retroviral activity (likely through impaired viral fitness). 
unatoč razvoju M184V, može osigurati rezidualnu antiretrovirusnu aktivnost (najvjerojatnije putem smanjene virulentnosti).
As well as the side effects listed below for Lamivudine Teva Pharma B.V., other conditions can develop during combination therapy for HIV. 
Uz nuspojave lijeka Lamivudin Teva Pharma B.V. spomenute u daljnjem tekstu mogu se razviti i druga stanja tijekom primjene kombinirane terapije za HIV.
Common: Nausea, vomiting, abdominal pain or cramps, diarrhoea. 
Poremećaji probavnog sustava Često: mučnina, povraćanje, bol ili grčevi u abdomenu, proljev
The observed half-life of elimination is 5 to 7 hours. 
U ispitivanjima je dokazano da je pri intravenoznoj primjeni srednji volumen raspodjele 1,3 l/kg i da je srednji poluživot eliminacije 5 -7 sati.
Nervous system disorders Common: Headache, insomnia. 
Često: glavobolja, nesanica.
NAME OF THE MARKETING AUTHORISATION HOLDER TEVA B.V. 
NAZIV NOSITELJA ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET TEVA B.V.
These may affect up to 1 in 10,000 people: 
Vrlo rijetke nuspojave Mogu se javiti kod najviše 1 od 10 000 ljudi:
Lamivudine Teva Pharma B.V. 300 mg film-coated tablets: 60 ml container of 30 film-coated tablets. 
Lamivudin Teva Pharma B.V. 300 mg filmom obložene tablete: spremnik od 60 ml s 30 filmom obloženih tableta.
How to take Lamivudine Teva Pharma B.V. 
Kako uzimati Lamivudin Teva Pharma B.V.
Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk of severe and potentially fatal hepatic adverse events. 
Rizik od nastupa ozbiljnih i potencijalno fatalnih jetrenih nuspojava povećan je u bolesnika koji su kronični nositelji virusa hepatitisa B ili C i koji su na kombinacijskoj antiretrovirusnoj terapiji.
Musculoskeletal and connective tissue disorders Common: Arthralgia, muscle disorders. 
Često: artralgija, mišićni poremećaji
If you get any symptoms of infection while you are taking Lamivudine Teva Pharma B.V.: Tell your doctor immediately. 
Ako zadobijete bilo koji od simptoma infekcije prilikom uzimanja lijeka Lamivudin Teva Pharma B.V.:
What Lamivudine Teva Pharma B.V. contains 
Lamivudine Teva Pharma B.V. sadrži natrij
1206 paediatric patients aged 3 months to 17 years enrolled in the ARROW Trial (COL105677) and were dosed according to the weight-band dosing recommendations in the World Health Organisation treatment guidelines (Antiretroviral therapy of HIV infection in infants and children, 2006). 
ispitivanje ARROW (COL105677) bilo je uključeno 1206 pedijatrijskih bolesnika u dobi od 3 mjeseca do 17 godina, kojima su se lijekovi dozirali sukladno preporukama za doziranje prema tjelesnoj težini,
• being sick (vomiting) 
• mučnina • povraćanje
Lamivudine Teva Pharma B.V. 300 mg film-coated tablets Each film-coated tablet contains 300 mg lamivudine. 
Lamivudin Teva Pharma B.V. 300 mg filmom obložene tablete Jedna filmom obložena tableta sadrži 300 mg lamivudina.
2 to 12 years (N=19) PENTA 15 3 to 36 months (N=17) 
3-36 mjeseci (N=17)
This may be administered as either 75 mg (one-half of a 150 mg tablet) taken in the morning and 150 mg (one whole 150 mg tablet) taken in the evening, or 225 mg (one and a half 150 mg tablets) taken once daily. 
Može se primijeniti kao 75 mg (pola tablete od 150 mg) ujutro i 150 mg (jedna cijela tableta od 150 mg) navečer ili kao 225 mg (jedna i pol tableta od 150 mg) jedanput na dan.
The study demonstrated that foetuses exposed in utero to the combination sustained a higher level of nucleoside analogueDNA incorporation into multiple foetal organs, and showed evidence of more telomere shortening than in those exposed to zidovudine alone. 
inkorporacije analoga nukleozida u više različitih fetalnih organa nego oni izloženi samo zidovudinu.
Administration of lamivudine tablets is bioequivalent to lamivudine oral solution with respect to AUC∞ and Cmax in adults. 
Primjena Lamivudin tableta bioekvivalentna je Lamivudin oralnoj otopini s obzirom na
Lamivudine Teva Pharma B.V. 300 mg film-coated tablets lamivudine 
Lamivudin Teva Pharma B.V. 300 mg filmom obložene tablete lamivudin
Lamivudine Teva Pharma B.V. 150 mg film-coated tablets Light grey, diamond shaped, biconvex film-coated tablet with approx. 14.5 mm length and 7.0 mm width - engraved with “L 150” and breakline on one side and breakline on the other. 
Svijetlo siva, bikonveksna filmom obložena tableta u obliku dijamanta, oko 14,5 mm duga i 7,0 mm široka, s utisnutom oznakom “L 150” i razdjelnim urezom na jednoj strani te razdjelnim urezom na drugoj strani.
White opaque PVC/PVdC - Aluminium blisters Pack sizes of 20, 30, 60, 80, 90, 100 or 500 film-coated tablets 
Veličina pakiranja: 20, 30, 60, 80, 90, 100 ili 500 filmom obloženih tableta
There have been reports of mitochondrial dysfunction in infants exposed in utero and/or post-natally to nucleoside analogues (see section 4.4). 
Također postoje uzvješća o disfunkciji mitohondrija u djece izložene nukleozidnim analozima in utero i/ili postnatalno
België/Belgique/Belgien Teva Pharma Belgium N.V./S.A. 
België/Belgique/Belgien Teva Pharma Belgium N.V./S.A. Tel/Tél: +32 38207373
As a general rule, when deciding to use antiretroviral agents for the treatment of HIV infection in pregnant women and consequently for reducing the risk of HIV vertical transmission to the newborn, the animal data as well as the clinical experience in pregnant women should be taken into account. 
HIV infekcije u trudnica, a time i za smanjenje rizika od vertikalnog prijenosa HIV-a na novorođenče,
Dosing according to weight bands is recommended for Lamivudine Teva Pharma B.V. tablets. 
Preporučuje se dozirati Lamivudin Teva Pharma B.V. tablete prema tjelesnoj težini.
How to store Lamivudine Teva Pharma B.V. 
Kako čuvati Lamivudin Teva Pharma B.V.
Osteonecrosis: Although the etiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV-disease and/or long-term exposure to combination antiretroviral therapy (CART). 
alkohola, tešku imunosupresiju, visoki indeks tjelesne mase), opisani su slučajevi osteonekroze,
Lamivudine Teva Pharma B.V. 150 mg film-coated tablets Lamivudine Teva Pharma B.V. 300 mg film-coated tablets 
150 mg filmom obložene tablete Lamivudin Teva Pharma B.V. 300 mg filmom obložene tablete
Paediatric population: In a study performed in paediatric patients (see section 5.1 ARROW study), lower rates of virologic suppression and more frequent viral resistance were reported in children receiving an oral solution of lamivudine as compared to those receiving the tablet formulation. 
ispitivanje ARROW), prijavljene su niže stope virusne supresije i češća rezistencija virusa u djece koja su primala oralnu otopinu lamivudina u usporedbi s djecom koja su primala tablete.
150 mg twice daily 
150 mg dvaput na dan 150 mg 150 mg jedanput na dan
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON - LAMIVUDINE TEVA PHARMA B.V. 150 MG FILM-COATED TABLETS 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU KUTIJA - LAMIVUDIN TEVA PHARMA B.V. 150 MG FILMOM OBLOŽENE TABLETE
• muscle pain and discomfort 
Poremećaji metabolizma i prehrane
To ensure the administration of the entire dose, the tablet(s) should ideally be swallowed without crushing. 
Tabletu se preporučuje uzeti cijelu (ne drobiti) kako bi se osigurao unos pune doze.
Lamivudine Teva Pharma B.V. 150 mg film-coated tablets Each film-coated tablet contains 150 mg lamivudine. 
150 mg filmom obložene tablete Jedna filmom obložena tableta sadrži 150 mg lamivudina.
STATEMENT OF ACTIVE SUBSTANCE(S) Each film-coated tablet contains 300 mg of lamivudine. 
Jedna filmom obložena tableta sadrži 300 mg lamivudina
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON - LAMIVUDINE TEVA PHARMA B.V. 300 MG FILM-COATED TABLETS 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU KUTIJA - LAMIVUDIN TEVA PHARMA B.V. 300 MG FILMOM OBLOŽENE TABLETE
Children weighing at least 14 kg and less than 20 kg The usual dose of Lamivudine Teva Pharma B.V. is 150 mg a day. 
Za liječenje djece od navršena 3 mjeseca i tjelesne težine manje od 25 kg dostupna je i Lamivudin Teva Pharma B.V. tableta od 150 mg.
STATEMENT OF ACTIVE SUBSTANCE(S) Each film-coated tablet contains 150 mg of lamivudine. 
Jedna filmom obložena tableta sadrži 150 mg lamivudina
With this condition, parts of the bone tissue die because of reduced blood supply to the bone. 
Možete imati probleme s kostima Kod nekih se ljudi koji uzimaju kombiniranu terapiju za HIV javlja osteonekroza, bolest u kojoj dijelovi koštanog tkiva odumiru zbog smanjenog dotoka krvi u kost.
NAME OF THE MEDICINAL PRODUCT Lamivudine Teva Pharma B.V. 300 mg film-coated tablets lamivudine 
Uputa o lijeku: Informacije za korisnika Lamivudin Teva Pharma B.V. 300 mg filmom obložene tablete lamivudin
Respiratory, thoracic and mediastinal disorders Common: Cough, nasal symptoms. 
Često: kašalj, nazalni simptomi.
Uncommon: Transient elevations in liver enzymes (AST, ALT). 
Manje često: prolazni porast jetrenih enzima (AST, ALT) Rijetko: hepatitis
When you are being treated for HIV, it can be hard to tell whether a symptom is a side effect of Lamivudine Teva Pharma B.V. or other medicines you are taking, or an effect of the HIV disease itself. 
Teva Pharma B.V. ili drugih lijekova koje uzimate ili se radi o simptomu same bolesti.
Some people taking Lamivudine Teva Pharma B.V. or other combination treatments for HIV are more at risk of serious side effects. 
Rizik od pojave ozbiljnih nuspojava povećan je u nekih ljudi koji uzimaju Lamivudin Teva Pharma B.V. ili neku drugu kombiniranu terapiju za HIV.
Each film-coated tablet contains 300 mg. - The other ingredients are: 
Jedna filmom obložena tableta sadrži 300 mg.
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING Tablet container - Lamivudine Teva Pharma B.V. 300mg film-coated tablets 
PODACI KOJI SE MORAJU NALAZITI NA UNUTARNJEM PAKIRANJU Spremnik za tablete - Lamivudin Teva Pharma B.V. 300 mg filmom obložene tablete
• if they have been taking combination therapy for a long time 
Ta će se bolest prije javiti kod ljudi: • koji duže vrijeme uzimaju kombiniranu terapiju
This can be given as 75 mg (half a 150 mg tablet) in the morning and 150 mg (one whole 150 mg tablet) in the evening, or 225 mg (one and a half 150 mg tablets) once a day as advised by your doctor. 
Može se primijeniti kao 75 mg (pola tablete od 150 mg) ujutro i 150 mg (jedna cijela tableta od 150 mg) navečer ili kao
Lamivudine Teva Pharma B.V. 150 mg film-coated tablets: 50 ml container of 60 film-coated tablets. 
150 mg filmom obložene tablete: spremnik od 50 ml s 60 filmom obloženih tableta.
Grey, diamond shaped, biconvex film-coated tablet - engraved with “L 300” on one side and plain on the other 
Kako Lamivudin Teva Pharma B.V. izgleda i sadržaj pakiranja Siva, bikonveksna, filmom obložena tableta u obliku dijamanta, s utisnutom oznakom „L 300“ na jednoj strani i bez oznake na drugoj strani
Light grey, diamond shaped, biconvex film-coated tablet - engraved with “L 150” and breakline on one side and breakline on the other. 
Kako Lamivudin Teva Pharma B.V. izgleda i sadržaj pakiranja Svijetlo siva, bikonveksna filmom obložena tableta u obliku dijamanta, s utisnutom oznakom „L 150“ i razdjelnom crtom na jednoj strani te razdjelnom crtom na drugoj strani.
This can be given as 75 mg (half a 150 mg tablet) twice a day (leaving approximately 12 hours between each dose), or 150 mg (one 150 mg tablet) once a day as advised by your doctor. 
Može se primijeniti kao 75 mg (pola tablete od 150 mg) dvaput na dan (s razmakom od približno 12 sati između doza) ili kao
Skin and subcutaneous tissue disorders Common: Rash, alopecia. 
Često: osip, alopecija Rijetko: angioedem
Adults, adolescents and children (weighing at least 25 kg) The recommended dose of lamivudine is 300 mg daily. 
Preporuke za doziranje u odraslih, adolescenata i djece (težine najmanje 25 kg): Klirens kreatinina (ml/min)
If you take more Lamivudine Teva Pharma B.V. than you should Accidentally taking too much Lamivudine Teva Pharma B.V. is unlikely to cause any serious problems. 
Ako uzmete više lijeka Lamivudin Teva Pharma B.V. nego što ste trebali
Each film-coated tablet contains 150 mg. - The other ingredients are: 
Jedna filmom obložena tableta sadrži 150 mg.
Each infusion lasts 10 or 30 minutes, according to the dose. 
Svaka infuzija traje 10 ili 30 minuta, ovisno o dozi.
It is given in four-week treatment cycles, on days 1, 2, 8, 9, 15 and 16 of each cycle. 
Primjenjuje se u terapijskim ciklusima u trajanju od četiri tjedna, 1., 2., 8., 9., 15. i 16. dana svakog ciklusa.
It is given to adults who have received at least one previous treatment for their cancer. 
Primjenjuje se u odraslih bolesnika koji su prethodno primili najmanje jednu terapiju protiv raka.
After the first week the dose is increased if the side effects are manageable. 
Nakon prvog tjedna doza se povećava ako se nuspojave mogu kontrolirati.
Kyprolis (carfilzomib) 
Kyprolis (karfilzomib)
What measures are being taken to ensure the safe and effective use of Kyprolis? 
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Kyprolis?
Other information about Kyprolis 
Ostale informacije o lijeku Kyprolis
This means that it blocks the proteasome, which is a system within the cells that breaks down proteins that are no longer needed. 
To znači da djeluje blokiranjem proteazoma, odnosno sustava unutar stanice koji razgrađuje bjelančevine koje više nisu potrebne.
Further information on the orphan designation can be found here: ema.europa.eu/Find medicine/Human medicines/Rare disease designation. 
Ovdje možete pronaći dodatne informacije o uvrštenju lijekova za rijetke bolesti: ema.europa.eu/Find medicine/Human medicines/Rare disease designation
Cancer cells have an increased need to produce and break down proteins because they multiply rapidly. 
Stanice raka imaju povećanu potrebu za stvaranjem i razgradnjom bjelančevina zbog toga što se brzo umnožavaju.
Kyprolis received a marketing authorisation valid throughout the EU on 19 November 2015. 
Lijek Kyprolis je dobio odobrenje za stavljanje lijeka u promet koje je na snazi u Europskoj uniji od 19. studenoga 2015.